Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

NCT ID: NCT00345189

Last Updated: 2009-07-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-02-28
• Study Completion Date: 2009-04-30

Brief Summary

This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.

Detailed Description

Heat shock protein 90 (Hsp90) is an ubiquitous molecular chaperone protein that is involved in folding, activation, and assembly of many proteins, including key mediators of signal transduction, cell cycle control, and transcriptional regulation. In cancer cells that are dependent upon Hsp90 client proteins, the degree to which clients are inhibited correlates closely with induction of growth inhibition and apoptosis with Hsp90 inhibitory drugs. The active pharmaceutical ingredient of CNF2024, CF1983 mesylate, is a synthetic, new chemical entity designed to inhibit Hsp90. CF1983 hada strong affinity for tumor derived Hsp90 and weaker affinity for Hsp90 isolated from normal cells or recombinant Hsp90.

Conditions

Tumors; Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dosing Schedule 1

Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.

Group Type: OTHER

CNF2024

Intervention Type: DRUG

CNF2024 capsules administered orally following 2 schedules:

• starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
• starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).

Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.

Dosing Schedule 2

Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).

Group Type: OTHER

CNF2024

Intervention Type: DRUG

CNF2024 capsules administered orally following 2 schedules:

• starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
• starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).

Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.

Interventions

CNF2024

CNF2024 capsules administered orally following 2 schedules:

• starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
• starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).

Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.

Intervention Type: DRUG

Other Intervention Names

Advanced Solid Tumors

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed solid tumor which has failed standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which effective therapy is not available
• At least 18 years of age
• Hematology: Absolute neutrophil count (ANC) > 1500 cells/mm3, platelet count > 100,000 cells/mm3 and hemoglobin >= 9 gm/L
• Hepatic: Bilirubin < 1.5 X upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN.
• Renal: Serum creatinine levels < 2.0 mg/dL or creatinine clearance > 60 mL/min
• Coagulation: international normalized ratio (INR) < 1.5 times normal
• Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels
• Normal electrocardiogram (ECG) with QTc <= 450 msec for men and <= 470 msec for women
• Estimated life expectancy of at least 3 months as determined by the Investigator
• Eastern Cooperative Oncology Group (ECOG) performance status <= 2
• Male and female patients of childbearing potential must practice effective double-barrier contraception during the study and continue contraception for 3 months after their last dose of study drug. Male patients must agree to not have intercourse with pregnant or nursing women during the study and for 3 months after their last dose of study drug, unless using double-barrier contraception. The only exceptions to double-barrier contraception are: Patient or partner is surgically sterile,female patient is postmenopausal for at least 1 year before screening or patient abstains from sexual intercourse, at the discretion of the Investigator

Exclusion Criteria

• Pregnant or nursing women, women of child-bearing age not using reliable means of contraception.
• Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less from chemotherapy-induced toxic effect, except alopecia, is required.
• Participation in any investigational drug study within 28 days prior to CNF2024 administration
• Active infection requiring intravenous antibiotic treatment
• Patients with second malignancy requiring active treatment (except hormonal therapy)
• Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure)
• Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
• Problems with swallowing or malabsorption
• Chronic diarrhea (excess of 2-3 stools/day above normal frequency)
• Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
• Major surgery of the stomach or small intestine
• Adrenal dysfunction > Grade 2
• Patients with diabetes (your doctor will discuss if you are eligible for this study)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biogen

INDUSTRY

Sponsor Role: lead

Responsible Party

Biogen Idec

Principal Investigators

Biogen Idec Medical Monitor, MD

Role: STUDY_DIRECTOR

Biogen

Locations

Research site

Scottsdale, Arizona, United States

Research site

New Haven, Connecticut, United States

Research site

San Antonio, Texas, United States

Research site

Sutton, Surrey, United Kingdom

Countries

United States; United Kingdom

Other Identifiers

120ST101

Identifier Type: -

Identifier Source: secondary_id

CNF2024-ST-05003

Identifier Type: -

Identifier Source: org_study_id